Ryanodine receptor 2

Ryanodine receptor 2
Name	Ryanodine receptor 2
Organism	Homo sapiens
Uniprot	P21817
Gene	RYR2

Ryanodine receptor 2 is a large intracellular calcium release channel predominantly expressed in human cardiac tissue. It is essential for cardiac excitation–contraction coupling and is implicated in inherited arrhythmia syndromes, heart failure, and stress-related cardiomyopathies. Research on this channel spans molecular biology, structural biology, electrophysiology, and clinical cardiology.

Structure and Function

Ryanodine receptor 2 is a homotetrameric macromolecular complex composed of four ~565-kDa subunits that form a transmembrane pore in the sarcoplasmic reticulum. Structural studies using cryo-electron microscopy from laboratories associated with the Max Planck Society, Harvard University, and Stanford University resolved cytosolic and transmembrane domains, revealing modular architectures analogous to other large ion channels studied by groups at the MRC Laboratory of Molecular Biology and Cold Spring Harbor Laboratory. The channel's pore-forming region resembles architectures described for the nicotinic acetylcholine receptor and channels investigated at the Salk Institute and Rockefeller University. Functionally, RYR2 mediates calcium-induced calcium release triggered by L-type calcium channels characterized in work at University of Oxford, Columbia University, and University of Pennsylvania.

Physiology and Role in Cardiac Excitation–Contraction Coupling

In ventricular myocytes, RYR2 cooperates with the cardiac dihydropyridine receptor (Cav1.2) characterized by investigators at Yale University and Johns Hopkins University to amplify calcium entry into a large cytosolic transient that activates sarcomeric proteins described in historical studies from University of Cambridge and McGill University. The temporal fidelity of RYR2 gating underlies heartbeat regularity studied in clinical programs at Mayo Clinic, Cleveland Clinic, and Mount Sinai Hospital. Dysregulated RYR2-mediated release contributes to arrhythmogenesis in contexts examined by research centers such as National Institutes of Health and European Society of Cardiology investigators.

Regulation and Interacting Proteins

RYR2 activity is modulated by accessory proteins and post-translational modifications identified by multidisciplinary teams at institutions including University College London, Karolinska Institutet, and ETH Zurich. Interacting partners include FKBP12.6 (identified in collaborations involving Institute Pasteur), calmodulin (studied at University of Cambridge), and calsequestrin2 (cited by groups at University of Milan), each described in landmark papers from Princeton University and University of California, San Francisco. Phosphorylation by kinases such as protein kinase A and CaMKII was elucidated in research programs at Massachusetts General Hospital and Vanderbilt University. Oxidative modification and nitrosylation mechanisms were investigated in laboratories at Imperial College London and the Karolinska University Hospital.

Genetic Variants and Associated Diseases

Pathogenic variants in the RYR2 gene were first linked to catecholaminergic polymorphic ventricular tachycardia in cohorts studied at Hôpital Pitié-Salpêtrière and Great Ormond Street Hospital. Subsequent genetic epidemiology from Children's Hospital of Philadelphia and Hospital for Sick Children expanded associations to arrhythmogenic right ventricular cardiomyopathy and sudden unexplained death, with genotype–phenotype correlations reported by consortia including researchers from Stanford University and University of Tokyo. Large-scale sequencing projects coordinated by the 1000 Genomes Project and Exome Aggregation Consortium catalogued population variation, aiding variant interpretation by clinical genetics groups at Royal Brompton Hospital and John Radcliffe Hospital.

Pharmacology and Modulators

Pharmacological modulation of RYR2 has been pursued by academic and industry labs at Pfizer, GlaxoSmithKline, and Novartis as well as university groups at Duke University and Brown University. Classic ligands, including ryanodine isolated in natural products studies linked to researchers at University of California, Berkeley, and tetracaine, were foundational tools. More recent small-molecule modulators such as JTV519 (K201) and dantrolene emerged from collaborative studies between Kyoto University and industrial partners, while drugs affecting upstream signaling pathways—beta-adrenergic blockers used in randomized trials at Cleveland Clinic and Brigham and Women's Hospital—indirectly influence RYR2 function. Novel therapeutic strategies are being tested in clinical trials registered by networks including the European Medicines Agency and the U.S. Food and Drug Administration.

Experimental Models and Research Methods

Investigations of RYR2 utilize heterologous expression systems developed in labs at University of California, San Diego and University of Washington, genetically engineered mouse models produced at centers such as The Jackson Laboratory and Wellcome Trust Sanger Institute, and human induced pluripotent stem cell–derived cardiomyocytes differentiated by teams at Stanford University and University of Cambridge. Techniques include patch-clamp electrophysiology refined at University of Gothenburg, calcium imaging pioneered at Karolinska Institutet, single-particle cryo-EM performed at facilities including Diamond Light Source, and proteomics workflows developed at Max Planck Institute for Biochemistry. Translational studies bridging basic and clinical science occur through collaborations involving National Heart, Lung, and Blood Institute and multicenter consortia such as networks coordinated by the European Society of Cardiology.

Category:Ion channels Category:Cardiac proteins